ImageneBio, Inc. (IMA)
NASDAQ: IMA · Real-Time Price · USD
6.24
+0.33 (5.58%)
At close: Mar 16, 2026, 4:00 PM EDT
6.20
-0.04 (-0.64%)
After-hours: Mar 16, 2026, 4:00 PM EDT
ImageneBio Revenue
In the year 2025, ImageneBio had annual revenue of $800.00K, down -77.14%.
Revenue (ttm)
$800.00K
Revenue Growth
-77.14%
P/S Ratio
83.50
Revenue / Employee
n/a
Employees
n/a
Market Cap
66.48M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 800.00K | -2.70M | -77.14% |
| Dec 31, 2024 | 3.50M | -5.66M | -61.79% |
| Dec 31, 2023 | 9.16M | -6.46M | -41.35% |
| Dec 31, 2022 | 15.62M | -15.37M | -49.59% |
| Dec 31, 2021 | 30.99M | 21.79M | 237.01% |
| Dec 31, 2020 | 9.19M | -4.56M | -33.15% |
| Dec 31, 2019 | 13.75M | 12.76M | 1,289.19% |
| Dec 31, 2018 | 990.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| TScan Therapeutics | 10.33M |
| Alterity Therapeutics | 4.43M |
| Mereo BioPharma Group | 500.00K |
| MediciNova | 409.66K |
| Entera Bio | 124.00K |
| InflaRx | 73.73K |
| eXoZymes | -700.00 |
IMA News
- 6 days ago - ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update - GlobeNewsWire
- 18 days ago - ImageneBio to Participate in Leerink Global Healthcare Conference - GlobeNewsWire
- 4 weeks ago - ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer - GlobeNewsWire
- 4 months ago - ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team - GlobeNewsWire
- 4 months ago - ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences - GlobeNewsWire
- 8 months ago - ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 8 months ago - Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million - GlobeNewsWire
- 8 months ago - Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company - GlobeNewsWire